Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00OGX
|
|||
| Former ID |
DIB011959
|
|||
| Drug Name |
Anapsos
|
|||
| Synonyms |
Psoriacen; EQA-00; Polypodium leucotomos extract, ASAC
Click to Show/Hide
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Approved | [1] | |
| Company |
ASAC Pharmaceutical International AIE
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphoid cell adhesion molecule expression (LCDME) | Target Info | Modulator | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.